Financials data is unavailable for this security.
Inc stmt in USDIncome statement in USD
Year on year
Novartis AG's net income fell -62.26% from 17.78bn to 6.71bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 34.01% to 35.11%.
|Net profit margin||13.27%|
|Return on assets||4.92%|
|Return on equity||9.19%|
|Return on investment||6.14%|
Cash flow in USD
Novartis AG increased its cash reserves by 49.91%, or 2.33bn. The company earned 11.48bn from its operations for a Cash Flow Margin of 23.24%. In addition the company used 3.44bn on investing activities and also paid 5.31bn in financing cash flows.
|Cash flow per share||5.07|
|Price/Cash flow per share||17.95|
|Book value per share||28.97|
|Tangible book value per share||2.83|
Balance sheet in USD
|Total debt/total equity||0.4371|
|Total debt/total capital||0.304|
Growth rates in USD
Year on year, growth in dividends per share marginally increased 0.25% while earnings per share excluding extraordinary items fell by -2.83%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
|Div yield(5 year avg)||3.57%|
|Div growth rate (5 year)||2.45%|
|Payout ratio (TTM)||98.50%|
|EPS growth(5 years)||-5.83|
|EPS (TTM) vs |
TTM 1 year ago